drugset / Trial / NCT01209026
Corrected QT (QTc) Study With Flucticasone Furoate and GW642444
RandomizedCrossoverTriple-blindTreatment
Summary
A randomised, placebo controlled thorough QTc study to evaluate the effect of repeat dose FF/GW642444M combination, with moxifloxacin as a positive control, on the QTc interval in healthy male and female subjects. Key assessments will include 12- lead electrocardiogram (ECG) and pharmacokinetic (PK) parameters, along with safety being assessed by blood pressure, heart rate, clinical laboratory safety tests, and collection of adverse events.
Timeline
- Start
- 2010-06-23
- Primary completion
- 2011-01-04
- Completion
- 2011-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone Furoate | Other / unclassified | 200 ug | Inhaled |
| Subject | Fluticasone Furoate | Other / unclassified | 800 ug | Inhaled |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Vilanterol | Other / unclassified | 25 ug | Inhaled |
| Subject | Vilanterol | Other / unclassified | 100 ug | Inhaled |